CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Nano Nuclear Energy Inc.

NNE
$930MSmall Cap

Next catalyst

No upcoming catalyst in our data

No upcoming FDA decision, filing or trial readout is on file for NNE. That does not mean none is planned.

Get an email about NNE's next catalysts

Track Nano Nuclear Energy (NNE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

1 upcoming event in our data (earnings).See the timeline

Catalyst Timeline

1 upcoming, 0 past

Earnings

NNE Earnings Report

Nov 30, 2026

EPS Est: $-0.31 | FQ end Sep/2026 | Call: amc

Market Overview

Stock performance and key metrics

NASDAQElectric ServicesNuclear microreactorπŸ‡ΊπŸ‡ΈNorth AmericaNEW YORK

Nano Nuclear Energy is an American company focused on the development of nuclear microreactor technologies and related nuclear services, headquartered in New York City and Oak Ridge, Tennessee. The company is an official member of the United States Nuclear Industry Council (USNIC) and the Nuclear Institute based in the United Kingdom. It was selected as a founding member of the HALEU (High Assay Low Enriched Uranium) consortium of the United States Department of Energy.

Website
Drug Pipeline

No drugs found in this phase.

Frequently asked questions

When is Nano Nuclear Energy Inc.'s next FDA catalyst?β†’

CatalystAlert tracks every upcoming catalyst for Nano Nuclear Energy Inc. (NNE) β€” PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β€” each confidence-rated as confirmed, estimated or AI-detected.

How do I track NNE biotech catalysts?β†’

Add NNE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nano Nuclear Energy Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply